These press releases are intended for business journalists and analysts/investors
GSK has launched a new immunology research collaboration model – the Immunology Catalyst sabbatical program – designed to embed academic scientists in GSK laboratories with the goal to broaden scientific insight and drive major breakthroughs in applied immunology.
Australian Professor John Hamilton from the University of Melbourne was the first academic to join the program.
GSK prioritises whooping cough vaccine availability for those most at risk of the disease and confirms uninterrupted supply of Boostrix® to all Australian State, Territory and Federal Government vaccination programs where Boostrix is the vaccine of choice.
GSK is leading the pharmaceutical sector by being first in Australia to introduce a new framework for its medical education program and interactions with healthcare professionals to increase transparency.
Read more - GSK first in Australia with new business model for the pharmaceutical industry Read more
- Assistant Minister for Science Karen Andrews opens new vaccine facility in Boronia, Victoria
- GSK awarded $1 million Federal Government grant for advanced manufacturing project
- Three-year pilot to test commercialisation
Amgen and GSK to Work Together to Ensure a Smooth Transition for
Prolia® Patients and Their Physicians
Read more - Amgen reacquires all rights to Prolia® (denosumab) in Australia Read more
Australian researchers awarded $80,000 for breakthrough in immunity
Millions more children from the world’s poorest countries are being vaccinated against more diseases than ever before.
GSK Australia is proud to be partnering with the Australian Government to provide a quadrivalent (four-strain) influenza vaccine for the National Immunisation Program (NIP) for the 2016 season.
Dr Ginni Mansberg ambassador for ‘Tried-It-All’ hay fever campaign launched today
Read more - GSK and Sun Pharma complete Opiates transaction Read more